» Articles » PMID: 15185311

HBsAg Seroclearance in Chronic Hepatitis B in the Chinese: Virological, Histological, and Clinical Aspects

Overview
Journal Hepatology
Specialty Gastroenterology
Date 2004 Jun 9
PMID 15185311
Citations 65
Authors
Affiliations
Soon will be listed here.
Abstract

Few studies have examined Chinese patients with chronic hepatitis B who exhibit hepatitis B surface antigen (HBsAg) seroclearance. We comprehensively studied the biochemical, virological, histological, and clinical aspects of 92 patients with HBsAg seroclearance (median follow-up, 126 months). Ninety-two HBsAg-positive controls matched for age, sex, and duration of follow-up were also recruited. Liver biochemistry, serum hepatitis B virus (HBV) DNA levels, and development of clinical complications were monitored. Intrahepatic total and covalently closed circular (ccc) HBV DNA were measured quantitatively in 16 patients. HBV genotype was determined in 30 patients. The mean age at HBsAg seroclearance was 48.8 (+ 13.81) years. There was a significant improvement in serum alanine aminotransferase levels after HBsAg seroclearance (p<0.0001). Patients with genotype B had a higher chance of HBsAg seroclearance than those with genotype C (P =.014). Ninety-eight percent of patients had undetectable serum HBV DNA. Thirty-seven percent of patients had low titer of intrahepatic HBV DNA, mainly in the form of cccDNA (71%-100%). All 14 patients with liver biopsies had near normal histology. There was no difference in the risk of development of hepatocellular carcinoma (HCC) between patients with and without HBsAg seroclearance. However, the mean age of HBsAg seroclearance was significantly older in patients with HCC than in patients without HCC (P =.016). In conclusion, patients with HBsAg seroclearance had favorable biochemical, virological, and histological parameters. Intrahepatic HBV DNA level was low and predominantly in the form of cccDNA. However, HCC could still develop, particularly in patients with cirrhosis who had HBsAg seroclearance at an older age.

Citing Articles

Expanding treatment indications in chronic hepatitis B: Should we treat all patients?.

Hui R, Mak L, Fung J, Seto W, Yuen M Hepatol Int. 2025; .

PMID: 39961977 DOI: 10.1007/s12072-025-10785-8.


Risk factors for hepatocellular carcinoma: an umbrella review of systematic review and meta-analysis.

Wang J, Qiu K, Zhou S, Gan Y, Jiang K, Wang D Ann Med. 2025; 57(1):2455539.

PMID: 39834076 PMC: 11753015. DOI: 10.1080/07853890.2025.2455539.


Clinical Consequences of Hepatitis B Surface Antigen Loss in Chronic Hepatitis B Infection: A Systematic Literature Review and Meta-Analysis.

Morais E, Mason L, Dever J, Martin P, Chen J, Felton L Gastro Hep Adv. 2024; 2(7):992-1004.

PMID: 39130769 PMC: 11307919. DOI: 10.1016/j.gastha.2023.06.004.


Quantitative Measurement of Serum HBcrAg Can Be Used to Assess the Feasibility of Safe Discontinuation of Antiviral Therapy for Chronic Hepatitis B.

Wang Y, Tang H, Chen E Viruses. 2024; 16(4).

PMID: 38675872 PMC: 11055047. DOI: 10.3390/v16040529.


Factors Positively Correlated with Hepatitis B Surface Antigen Seroconversion in Chronic Hepatitis B.

Buechter M, Gunther A, Manka P, Gerken G, Kahraman A J Pers Med. 2024; 14(4).

PMID: 38673017 PMC: 11051014. DOI: 10.3390/jpm14040390.